特立帕肽与地舒单抗保守治疗胸腰椎骨质疏松性椎体骨折的影像学与功能结局比较
本研究回顾性纳入78例无神经功能缺损的胸腰椎骨质疏松性椎体骨折女性患者,分别接受特立帕肽(34例,每日20μg)或地舒单抗(44例,每6个月60mg)保守治疗6个月。两组影像学变形和功能结局无显著差异,但特立帕肽组骨折愈合伴椎旁骨桥形成(FUPB)发生率显著高于地舒单抗组(58.8% vs 25.0%,P=0.004)。
要点
- 特立帕肽与地舒单抗保守治疗胸腰椎骨质疏松性椎体骨折6个月时影像学变形和功能结局无显著差异。
- 特立帕肽组6个月FUPB发生率58.8%(20/34),高于地舒单抗组25.0%(11/44),P=0.004。
- 多因素logistic分析显示特立帕肽是达成FUPB的最显著因素(OR 4.486,P=0.012)。
核心结论
- 特立帕肽与地舒单抗虽药理机制不同,但在胸腰椎骨质疏松性椎体骨折保守治疗中显示出相似的影像学变形和功能结局。
- 特立帕肽组骨折愈合伴椎旁骨桥形成的发生率显著高于地舒单抗组。
研究设计与样本
- 回顾性研究纳入78例平均年龄74.69±7.66岁(范围60-92岁)的无神经功能缺损胸腰椎骨质疏松性椎体骨折女性患者。
- 患者接受特立帕肽(T组34例,每日一次20μg)或地舒单抗(D组44例,每6个月一次60mg)保守治疗6个月。
- 评估指标包括后凸角、节段性椎体后凸角和压缩比等影像学变形、骨折愈合伴椎旁骨桥形成(FUPB)发生率,以及视觉模拟量表(VAS)和Oswestry功能障碍指数(ODI)功能结局,评估时间点为0、3、6个月。
主要发现
- 两组在0、3、6个月时的影像学变形和功能结局均无显著差异(P > 0.05)。
- 6个月时FUPB发生率T组为58.8%(20/34),D组为25.0%(11/44),差异有统计学意义(P = 0.004)。
- 多因素logistic分析中,特立帕肽是达成FUPB的最显著统计学因素(OR 4.486,P = 0.012)。
关键数值与推荐
- 特立帕肽用法:每日一次20μg,治疗6个月。
- 地舒单抗用法:每6个月一次60mg,治疗6个月。
- FUPB定义为骨折愈合伴椎旁骨桥形成,6个月时T组发生率58.8%(20/34)vs D组25.0%(11/44),P = 0.004。
- 多因素分析中特立帕肽对FUPB的OR为4.486(P = 0.012)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Teriparatide and denosumab, anti-osteoporosis medications with different mechanisms, have been widely used in the patients with osteoporotic vertebral fracture (OVF) considered as advanced osteoporosis. Teriparatide has been shown to enhance bone formation and fracture healing in OVF, but there are still no sufficient evidences discussing about the role of denosumab in newly developed OVF. In this study, we found the similar radiological deformation and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar (TL) OVF, and teriparatide showed a more frequent incidence of fracture union with paravertebral bone bridge formation compared to denosumab. INTRODUCTION: Teriparatide and denosumab have been widely used to treat advanced osteoporosis and prevent subsequent fractures in patients with OVCF. Unlike teriparatide, which is considered to be effective in fracture healing, there is still no clear role and evidence for the effect of denosumab in acute OVCF. This study compared the radiological and functional outcomes of conservative treatment with teriparatide and denosumab in TL-OVF. METHODS: This retrospective study enrolled 78 women with mean age of 74.69 ± 7.66 (60-92) years diagnosed as a TL-OVF with no neurological deficits. All patients were treated conservatively with teriparatide (34 of group T, once-daily 20 μg) or denosumab (44 of group D, once-6 months 60 mg) for 6 months. We evaluated the radiological deformation (kyphotic angle, segmental vertebral kyphotic angle, and compression ratio) and the incidence of fracture union with paravertebral bone bridge formation (FUPB) and functional outcomes using the visual analog scale (VAS) and Oswestry Disability Index (ODI) at 0, 3, and 6 months. RESULTS: In the radiological deformation and functional outcomes, there were no significant differences at 0, 3, and 6 months between the two groups (P > 0.05). However, the incidence of FUPB at 6 months was higher in group T (20/34, 58.8%) compared to group D (11/44, 25.0%) (P = 0.004), and teriparatide was the most statistically significant factor for achieving FUPB (OR 4.486, P = 0.012) in multivariable logistic analysis. CONCLUSIONS: Teriparatide and denosumab, despite of their different pharmacological mechanisms, showed similar radiological deformation and functional outcomes in the conservative treatment of TL-OVF. However, teriparatide showed a significantly higher incidence of fracture union with paravertebral bone bridge formation.
引用
- Jeon S, Yu D, Kim S, et al. Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture. Osteoporos Int. 2024. PMID: 38261013. doi:10.1007/s00198-024-07025-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。